A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
A phase 1/2 trial of Rezvilutamide, Tazemetostat in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer is a phase 1/2 interventional study registered as NCT07407283 by Jiangsu HengRui Medicine Co., Ltd., with 100 participants planned, started 2026-04-08 and due to reach its primary completion in 2027-11. Interventions recorded: SHR-4394, Rezvilutamide, HRS-5041 Tablets, Tazemetostat. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer
Phase
Phase 1/2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
Enrolled
100
Similar pages
not linked directly; found by shared links- TrialA Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
- TrialA Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
- TrialA Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
- TrialA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- TreatmentHRS-4357
- TreatmentHS-20093